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ABSTRACT 
Objective: Several studies suggest that patients with ankylosing spondylitis 
(AS) have an increased risk of cardiovascular disease. This study aimed to 
evaluate the effects of a 12-week individually heart rate-monitored, 
moderately intensive cardiovascular training on cardiovascular fitness and 
perceived disease activity in AS patients. 
Methods: Patients diagnosed with AS according to modified New York 
criteria were randomised to either ‘cardiovascular training’ or ‘attention 
control’. The training group performed three cardiovascular trainings per 
week. All participants attended one weekly usual care flexibility training. 
Attention control contained regular discussion groups on coping strategies. 
Adherence was self-monitored. Assessments were performed at baseline 
and after the intervention period of 3 months. Physical fitness was the 
primary endpoint, measured in watts using a submaximal bicycle test 
following the PWC75% protocol. All analyses controlled for gender, age, 
body mass index, baseline fitness and physical activity levels, and BASDAI.   
Results: Of 106 AS patients enrolled, 40% were women, mean age was 49 
(SD +/-12) years.  76.5% of the training group reported exercising at least 
three times a week. At 3 month follow-up, fitness level in the training group 
was significantly higher than in the control group (90.32 (SD 4.52) vs.109.84 
(SD 4.72) respectively, p=0.001), independent of other covariates. Average 
BASDAI total score was 0.31 points lower (p = 0.31) in the training group, 
reaching significance for the ‘peripheral pain’ subscore (1.19; p=0.01), but 
not for ‘back pain’ or ‘fatigue’. 
Conclusions: Cardiovascular training, in addition to flexibility exercise, 
increased fitness in AS patients and reduced their peripheral pain.   
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Significance and Innovations  
• AS patients carry an increased risk of cardiovascular disease. This is 
the first large trial with AS patients focusing on increased 
cardiovascular fitness. 
• Many exercise studies do not achieve sufficient therapeutic validity. 
This study achieved sufficient therapeutic dose, including sufficient  
adherence of the patients to the training programme (and the study 
protocol). 
• AS patients are able to perform intensive cardiovascular training 
without increasing disease activity.   
• This study provides basis for studying long-term effects of CV training 
on further parameters, e.g. biomarkers.  
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 Ankylosing Spondylitis (AS) is a chronic inflammatory rheumatic 
disease that affects the spine and iliosacral joints and is also associated with 
extraspinal manifestations, such as peripheral arthritis, enthesitis, uveitis or 
bowel inflammation (1). The ASAS/EULAR recommendations for the 
management of AS recommend drug therapy, such as non-steroidal anti-
inflammatory drugs (NSAIDs) and, in severe cases, TNF-alpha inhibitors, in 
combination with spinal flexibility exercise (2). Supervised flexibility exercises 
in AS patients have been shown to be effective in improving spinal flexibility, 
physical function, and patients’ well-being (3).  
Several observational studies suggest that AS patients carry an increased 
risk of cardiovascular disease (4-7). In addition to chronic inflammation, 
reduced physical activity due to disease activity, pain and fatigue may further 
contribute to AS-related cardiovascular disease (7, 8). Regarding physical 
activity, however, exercise recommendations in AS-guidelines focus on spine 
flexibility rather than cardiovascular training (2). It can be assumed that these 
recommendations are widely followed in AS exercise groups, meaning that 
cardiovascular training is not an established element in AS specific exercise.  
A secondary analysis based on the third Cochrane review updated in 
2008 included 12 randomised controlled trials on exercise interventions in AS 
patients (ten from the 2008 Cochrane review and two more recently 
published ones) and evaluated if the exercise programmes in trials for AS 
patients were intensive enough to be effective (9). This was determined 
according to the recommendations of the American College of Sports 
Medicine (ACSM), which summarize the current evidence for effective 
exercise interventions (10, 11). Exercise interventions are effective, if they 
achieve a physiological response, such as increased flexibility, muscular 
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strength and cardiovascular fitness, which is determined by the frequency, 
intensity and duration of corresponding exercises, as well as patients’ 
adherence (12). The secondary analysis could not determine conclusively the 
benefit of cardio-vascular training as all exercise programmes focused on 
flexibility training, while cardio-vascular fitness components were part of only 
five exercise programmes, with only one meeting the ACSM 
recommendations for cardiovascular training.  
In order to better define the role of cardiovascular training in AS 
patients we planned this study to test whether a training designed to improve 
cardio-vascular fitness is successful in AS patients attending standard 
flexibility exercise classes. We chose Nordic Walking (NW) as a simple 
cardio-vascular exercise mode that may attract also inactive individuals. 
Further, we assumed that NW would be especially suitable for AS patients 
because of its controlled loading on joints and spine and the enhanced spinal 
rotation supported by the use of the walking sticks (12, 13). 
 
Patients and Methods 
Study design  
 This randomised controlled trial was conducted at the Department of 
Rheumatology and the Centre on Aging and Mobility at the University 
Hospital of Zurich, in close collaboration with the AS patient organisation, the 
Swiss Ankylosing Spondylitis Association (SVMB, Schweizerische 
Vereinigung Morbus Bechterew). In addition, we involved a SVMB member in 
the planning and conduct of the study, ensuring that the trial addressed 
patient-relevant outcomes and that all the trial documents are understood by 
the target population and helping recruiting patients.     
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The Local Ethics Committees approved the study and all participants gave 
written informed consent. The study has been registered at the International 
Clinical Trials Registry (identifier NCT00913302).  
 
Participants 
Participants diagnosed with AS based on the modified New York 
criteria (14) were recruited from the SVMB membership registry, including 
approximately 2500 members and from rheumatology outpatient clinics and 
private practice rheumatologists in German-speaking regions of Switzerland. 
Additional inclusion criteria were age >18 years and sufficient German 
language ability skills. Exclusion criteria were moderate to severe heart 
disease (functional New York Heart Association Class III and IV) and inability 
to cycle on an ergometer bike. The most important reasons for non-
participation were ‘no interest’ and ‘no time’.  
Two recruitment and outdoor training periods from January to May and 
August to October respectively in two subsequent years ensured similar 
weather conditions for outdoor NW training.   
 
Randomisation and procedures 
Participants were randomised to the training group (cardiovascular training 
and flexibility exercise) or the control group (attention control and flexibility 
exercise) by sequentially numbered, concealed treatment allocations 
prepared in advance by an independent statistician. We used a stratified 
block randomisation procedure (block size 4) (15) with TNF-α inhibitor 
treatment (Yes/No) as the stratification variable. We stratified for treatment 
with TNF inhibitors because of their known effect on the secondary outcome 
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(BASDAI), which may influence the patients’ ability to perform a physical 
training.  
In this trial, participants and physiotherapists who instructed the NW 
programme were aware of the treatment assignment. However, the 
physiotherapists who performed baseline and follow-up assessments were 
blinded to the group allocation.   
 
Interventions:  
Cardiovascular training  
The training group performed a 12-weeks supervised NW training for 
30 minutes twice a week on individually monitored moderate heart rate (HR) 
intensity levels. Moderate HR intensity ranges of 55 – 75% of the HRmax were 
used for participants who reached less than 100 watts and 65 – 85% of 
HRmax were used for participants who reached at least 100 watts in the 
baseline bicycle test (10, 11). The intensity range was adjusted if an 
individual passed over the upper limit during at least 20 minutes. Participants 
with a low fitness status, i.e. having reached less than 100 Watts in the test 
and not able to perform the training in their individual lower fitness range for 
sufficient duration of at least 20 minutes, were first asked to keep walking for 
at least 20 minutes, and if this was achieved, to perform NW within the 
intensity range. All participants in the training group were provided with the 
NW equipment and a heart rate monitor. The NW training was performed in 
small groups of two to six participants and led by instructing physiotherapists. 
Furthermore, participants in the training group were asked to perform at least 
one additional unsupervised, but heart rate-monitored cardiovascular 
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training, NW or other endurance activities, e.g. outdoor or ergometer biking, 
to achieve at least three training units per week.  
All physiotherapists who instructed the cardiovascular training previously 
underwent a standardized 4-hour education session.  
 
Attention control  
Instead of the NW training, the control group was offered an ‘attention 
control intervention’, consisting of monthly 2.5-hours discussion groups on 
coping strategies and techniques of mindfulness-based stress reduction, led 
by a psychologist (16). 
 
Standard flexibility exercise 
 All study participants received the current standard of care and 
attended a weekly one-hour exercise group, supervised by a physiotherapist, 
with focus of spinal flexibility as offered by the Swiss AS Association 
throughout Switzerland.  
 
Training locations and adherence support  
Every effort was made to offer a training location closest to the home 
or work of the participants, and dates and times of group trainings most 
convenient for them, to facilitate participation. One of the two weekly 
supervised NW trainings could be attended on the same evening as the 
flexibility exercise class to reduce time constraints for the participants. All 
participants received an individual schedule and were asked to keep an 
adherence diary of all their supervised and unsupervised physical activities. 
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Assessments 
The primary outcome in this trial was cardiovascular fitness, assessed 
with a submaximal bicycle test following the Physical Work Capacity 
PWC75% protocol to estimate aerobic capacity (VO2 max) (17). A submaximal 
endurance test is considered more sensitive to change than a maximal 
endurance test (18). According to the PWC75 % protocol, heart rates at 55%, 
65% and 75% of the estimated age-related maximum heart rate are 
calculated and the Watts produced at these heart rate levels are measured. 
Although heart disease (NYHA III and IV) was an exclusion criterion, 
simultaneous electrocardiograms (ECG) were applied in all participants for 
safety reasons during exercise testing. The cardiologist reviewed all ECGs 
and if identifying any abnormality, comparison with the patient’s 
cardiovascular disease history was performed to decide whether the patient 
had to be excluded.  
 The secondary outcome was perceived disease activity assessed with 
the BASDAI (The Bath AS Disease Activity Index) on a 0-10 (none to very 
severe) numerical rating scale NRS (19). Predefined in our protocol, we 
assessed both the total BASDAI score and the subscales for spinal pain, 
peripheral pain and fatigue. 
 Additional exploratory outcomes were 1) AS-specific functional health, 
assessed with the BASFI (The Bath AS Functional Index) (20), the BASMI 
(The Bath AS Metrology Index) (21) and patient’s global assessment of 
disease activity, general pain and nocturnal pain, all measured on a 0-10 
NRS (22). 2)type, amount and intensity of physical activity (PA) by use of the 
OIMQ (Office in Motion Questionnaire) (23) and subsequently assigning 
METs ( metabolic equivalents) to each reported activity (24) and an 
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accelerometer (Actigraph, Manufacturing Technology Inc. (MTI, Fort Walton 
Beach, FL). The small waist-mounted device is worn for seven days, 
including a complete weekend, to calculate a reliable average physical 
activity per day (25, 26), given as counts/minute (=number of accelerations) 
and as minutes spent in moderate and vigorous activity, using the cut points 
defined by Swartz et al. (27). 3) psychological status, using the HADS-D 
(German version of Hospital Anxiety and Depression Scale), assessing 
anxiety and depression on two 7-item 0-3 scales, (no to severe problems) 
(28). 4) perceived general health using the EURO-Quol, applying a 0-100 
VAS (worst to best health) (29) and 5) lab data of disease activity 
(erythrocyte sedimentation rate ESR and C reactive protein CPR) and 
metabolism (cholesterol and triglycerides). Further we calculated the ASDAS 
using parameters from BASDAI and CRP (30).  
 
Sample size  
 We based our sample size calculation on the reported means and  
standard deviations from a similar exercise trial in patients with rheumatoid 
arthritis (31). To achieve a minimal clinically meaningful difference of 20% for 
the primary outcome, 49 patients in each group were needed to achieve 90% 
power to detect this difference.  
 
Statistical analysis 
Statistical analysis was performed on an 'intention-to-treat' basis. 
ANOVA models were used to compare cardiovascular fitness levels, BASDAI 
total and sub-scores and the exploratory outcome variables at follow-up. The 
crude models controlled for TNF-α treatment status as stratification variable 
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and baseline level of the characteristic. The fully adjusted models additionally 
controlled for age, sex, BMI, smoking status, and baseline levels for 
perceived disease activity, physical activity and fitness. The data were 
analysed using SAS v.9.2 statistical software (©2002 – 2008 by SAS 
Institute, Inc., Cary NC, USA). All statistical tests were two-sided with 
significance level set at 0.05. 
 
Results 
 From a total of 185 AS patients who attended the information meetings 
about the study, 106 confirmed their participation and met the inclusion 
criteria. 47 of these were enrolled in the first and 59 in the second year of 
enrollment (figure 1) {image 1}. Baseline characteristics of the two groups 
were similar (table 1), formal statistical testing detected no significant 
differences. Participants had no history of heart disease. No signs of 
coronary ischemia were observed in the ECGs. The cardiologist identified 3 
patients with ECGs suggestive of left ventricular hypertrophy and reviewed 
these patients’ cardiovascular history. No exclusions were performed.  
Although not assessed systematically, participants seemed to have a low 
cardiovascular risk: 19 patients were on antihypertensive medication, six of 
them additionally on aspirin and/or statin.   
Based on the physiotherapists’ protocols for group adherence and on 
participants’ diary, 74.6% of the training group performed at least three 
training units per week (mean = 3 trainings/week), i.e. two NW training 
sessions and one additional unsupervised cardio-vascular training unit, but 
only 25% of the control group performed three or more trainings per week 
(mean = 1 training per week) .  
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In a few patients (n=4) who were quite fit already at the beginning and who 
exercised in the upper intensity range i.e. 65 – 85% of HRmax, , the upper 
limit was increased to 90% of HRmax, during the study period; all less fit 
participants kept exercising in the lower intensity range during the study 
period, but at the end all of them achieved the required intensity and duration 
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Treatment effects 
Primary outcome: At 3 month follow-up, both the minimally and the 
fully adjusted ANOVA model showed a significant benefit in fitness level 
(expressed in Watts) in the training group compared to the attention control 
group. In the minimally adjusted model mean (SE) Watts in the training group 
were 107.98 (3.98), compared to 87.78 (3.87) in the controls (p=0.0004). In 
the fully adjusted model mean (SE) Watts in the training group were 109.84 
(4.72) compared to 90.32 (4.52) in the control group (p=0.001, 95% CI 9.18-
31.24), the difference thus being independent of the covariables (table 2).  
At baseline, two patients in each group were not able to perform the 
PWC75% test due to their low fitness. At follow up, no patient in the training 
group, but six patients in the control group were not able to fulfil the 
PWC75% test protocol, which we consider related to the training effect.  
The OIMQ questionnaire and the accelerometer were administered before 
and shortly after the intervention period, assessing the participants’ actual 
physical activity. It may thus not reflect their amount of physical activity 
during the intervention period, but rather their usual physical activity. On 
average this seemed to be the same in both groups after study conclusion, 
although the NW participants had performed substantial more 
14 
 
 
Secondary outcome (table 2). There was no difference between the two 
groups in the BASDAI total score at 3 months follow up. For the subscores, 
we found a significantly lower level of peripheral pain in the training group 
1.32 (0.34) compared to 2.36 (0.33) (p=0.02) in the controls (95% CI –1.89 to 
-0.18), while the subscores for fatigue and neck-back-hip pain were not 
different between groups.  
Additional exploratory outcomes (table 3). There were no significant 
differences between the two groups regarding the exploratory endpoints, 
neither in functional measures nor in biomarkers. With respect to the Bath 
indices, functional limitations were generally low.
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Discussion 
To our knowledge, this is the first controlled trial to test the effect of cardiovascular 
training in addition to standard flexibility exercise in AS patients. The results 
demonstrate that an appropriately designed and conducted cardiovascular training 
that meets recommended standards leads to significantly improved cardiovascular 
fitness in AS patients. NW as a strategy to improve cardiovascular fitness in AS 
patients was well tolerated by the participants, who, despite having a chronic 
inflammatory condition, were able to exercise frequently, moderately intensive and 
over a longer period without increasing their disease activity or pain. This 
supported high adherence to the intervention, which is key when it comes down to 
exercise studies. The clear association between exercise participation rates and 
achieved fitness level increased the credibility of the diary protocols and 
demonstrated adherence to the study protocol. The fact that resting HR did not 
decrease to the expected extent in the training group may be due to the relatively 
short training period. Furthermore, the decrease in HR after a course of exercise 
training has been described mainly in patients with established coronary heart 
disease of chronic heart failure (32, 33). 
Regular physical activity and aerobic exercise training are related to a reduced risk 
of coronary events in healthy individuals (34-36) subjects with coronary risk factors 
(37) and established coronary artery disease (32). Therefore, physical activity and 
aerobic exercise training are recommended by international guidelines for primary 
and secondary cardiovascular prevention (38, 39). 
We show that cardiovascular training is safe and feasible in AS patients and 
increases their fitness level, independent of their initial fitness level. Whether this 
benefit translates into the prevention of cardiovascular disease needs to be tested 
in a larger longer-term clinical trial. Notably, we measured biomarkers of CV-health 
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as exploratory endpoints (cholesterol, triglycerides), which did not improve 
significantly in the training group over control, possibly also due to the short follow-
up.  Unfortunately, HDL and LDL cholesterol has not been analysed separately. 
Therefore, we could only speculate about potential changes in HDL/LDL ratio with 
an increase of protective HDL levels and an according decrease of LDL levels 
after the training course. Our initial assumption was that NW training may also 
improve fatigue, assessed by BASDAI. Fatigue is one of the predominant 
complaints of AS patients and has been shown to be influenced by physical 
activity (40). However, although many NW participants reported to feel more 
energy after the training and some cardiovascular training studies in RA showed 
positive effects on fatigue, even in rather small samples (41, 42), we could not 
demonstrate changes in BASDAI total score or in the fatigue subscore in this 
group.  Disease activity in our sample was generally low because we recruited 
patients already treated according  to current standards including the availability of 
TNF inhibitors and the majority of our patients didn’t classify as ‘fatigued’ (43), 
which may partly explain our results.  
Interestingly however, participants in the training group reported a significant 
improvement in the ‘peripheral pain’ subscale over control, which addresses 
another important endpoint in patients with AS. Literature for effects on pain in 
musculoskeletal diseases by cardiovascular training is scarce, only two early 
studies in rheumatoid arthritis (RA) (31, 44), found that the dynamic exercise 
groups significantly decreased the number of clinically active joints. The 2006 
Cochrane review on dynamic exercise therapy for treating rheumatoid arthritis, 
evaluating six trials, however concluded that there were no positive, but also no 
negative effects on pain (45).  
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Our trial had several strengths. First, it was the largest exercise trial in AS patients 
so far and, in addition to providing an intervention based on the current and 
established ASCM recommendations, we chose a training strategy that was 
feasible and well tolerated by participants. Further, we assured high quality 
outcome assessments by blinding the assessment physiotherapists at baseline 
and follow-up to the treatment allocation. Also, our study was appropriately 
powered to detect a statistically significant difference for the primary outcome.  
Moreover, the attention control intervention lends credibility to the training effect of 
NW.   
There are also limitations to our study. These include a limited sample size for the 
secondary and exploratory endpoints tested and the short follow-up of 3 months. 
Further, no efforts were made to support the participants’ achieved fitness levels. 
However support is usually necessary to keep patients on their achieved physical 
activity levels (46). Physiotherapists’ coaching of early-stage RA patients, in terms 
of two face-to-face meetings and subsequent regular telephone calls, has been 
shown to successfully support their physical activity adherence over one year (47). 
However, after another year without any support, no differences in physical activity 
levels were present compared to the controls (48). It seems that even distance-
coaching is effective to keep people active and to maintain exercise effects.   
 
In summary, the improved cardiovascular fitness and the significant improvement 
in BASDAI peripheral pain support the inclusion of NW as a cardiovascular training 
strategy in patients with AS. Future research should test the long-term effects of 
NW on cardio-vascular health in patients with AS.  
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Table 1: Baseline characteristics of participants 
 
 Training group 
(n=53) 
Control group 
(n=53) 
p 
Men, No (proportion) 34 (64%) 34 (64%) 1.00 
Age, years, mean (SD) 50.1 (11.9) 47.6 (12.4) 0.29 
Disease duration, (years)  
median (range) 
9 (0.5 -45) 8 (0.5 – 39) 0.60 
BMI (kg/m2), mean (SD) 25.2 (4.1) 25.5 (4.3) 0.71 
Smokers (proportion) 11 (20%) 16 (30%) 0.37 
TNF treatment yes (%) 15 (28%) 16 (30%) 1.00 
Fitness (in Watts) 91.3 (37.4) 101.4 (45.5) 0.21 
Resting heart rate 82.3 (11.4) 82.1 (13.5) 0.94 
Heart rate at end of test  130.5 (9.6) 132.7 (10.3) 0.29 
BASDAI (0-10) 3.3 (1.9) 3.6 (2.1) 0.57 
BASDAI fatigue (0-10) 4.4 (2.4) 5.0 (2.7) 0.27 
BASDAI neck-back-hip pain (0-10) 3.8 (2.5) 4.2 (2.7) 0.65 
BASDAI joint pain (0-10) 2.2 (2.3) 2.7 (2.6) 0.36 
BASG night pain (0-10) 3.1 (2.8) 2.9 (2.8) 0.59 
BASG pain (0-10) 3.2 (2.0) 3.5 (2.5) 0.80 
BASG disease activity (0-10) 3.7 (2.3)  4.2 (3.1) 0.72 
BASFI (0-10) 2.4 (1.9) 2.4 (2.1) 0.92 
BASMI (0-10) 2.9 (2.1) 2.8 (1.9) 0.99 
OIMQ (MET per week) 71.8 (39.1) 78.4 (58.5) 0.89 
Accelerometer, counts/min), mean 
(SD) per day 
336 3 (184.9) 370.5 (145.0) 0.18 
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Accelerometer, moderate activity 
(min/week) 
145.9 (54.2) 170.4 (64.5) 0.09 
PA (Accelerometer, units of 
vigorous activity) 
11.1 (9.4) 13.6 (12.9) 0.50 
HADS Anxiety (0-21) 6.9 (5.3) 6.7 (4.5) 0.92 
HADS Depression (0-21) 5.2 (4.4) 5.0 (4.5) 0.70 
EURO-Quol Health score (0-100) 64.5 (22.0) 65.9 (21.2) 0.75 
ASDAS(CRP) 7.5 (9.8) 6.4 (8.7) 0.73 
CRP (mg/l) 2.2 (0.8) 2.3 (1.0) 0.40 
Cholesterol (mmol/l) 5.4 (0.9) 5.3 (1.0) 0.41 
Triglycerides (mmol/l) 1.1 (0.6) 1.4 (1.0) 0.07 
 
Tests used: χ2 test for categorical variables, nonparametric statistics (Wilcoxon 
rank-sum test) for all continuous variables. 
Values are means and SD, unless stated otherwise.  
SD, Standard deviation; BMI, body mass index; TNF, tumor necrosis factor; CRP, 
C-reactive protein; AS DASCRP, ankylosing spondylitis disease activity score 
(calculated with CRP values); BASDAI, Bath AS Disease Activity Index; BASFI = 
the Bath AS Functional Index; BASMI = Bath AS Metrology Index.  
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Table 2: Primary and secondary outcomes at 3 months follow up 
Primary outcome Minimally adjusted ANOVA model** Multivariate adjusted ANOVA model*** 
 Exercise 
Group  
Control 
Group  
P value Exercise 
Group  
Control 
Group  
P value 
Fitness level (Watts)* 107.98 (3.98) 87.78 (3.87) 0.0004 109.84 (4.72) 90.32 (4.52) 0.001 
Secondary outcome             
BASDAI score total (0-10)* 3.07 (0.20) 3.35 (0.20) 0.33 2.84 (0.24) 3.15 (0.23) 0.31 
BASDAI score fatigue  (0-10)            3.73 (0.32) 4.29 (0.32) 0.22 3.64 (0.39) 4.39 (0.37) 0.13 
BASDAI score neck-back-hip pain (0-10) 3.31 (0.33) 4.15 (0.30) 0.07 3.25 (0.38) 3.98 (0.36) 0.13 
BASDAI score joint pain (0-10) 2.05 (0.31) 2.74 (0.30) 0.11 1.32 (0.34) 2.36 (0.33) 0.02 
All values are means and standard deviation (SD), unless stated otherwise 
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Bold = Significant on 0.001 and 0.05 level respectively 
* baseline values given in table 1 
** adjusted for TNF alpha treatment (stratification variable) and baseline level of the characteristic 
*** adjusted for age, sex, BMI, smoking status, baseline physical activity, baseline perceived disease activity, TNF alpha and baseline 
of characteristic  
 
BASDAI = the Bath AS Disease Activity Index  
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Table 3: Additional exploratory outcomes 
Outcome Minimally adjusted ANOVA model* Multivariate adjusted ANOVA model** 
 Exercise 
Group  
Control 
Group  
P value Exercise 
Group  
Control 
Group  
P value 
BAS-G night pain (0-10) 3.00 (0.26) 2.63 (0.27) 0.32 2.26 (0.32) 2.64 (0.31) 0.34 
BAS-G pain (0-10) 3.25 (0.29) 3.39 (0.28) 0.74 3.13 (0.35) 3.20 (0.33) 0.88 
BAS-G disease activity (0-10) 4.05 (0.35) 3.74 (0.34) 0.52 3.87 (0.40) 3.59 (0.38) 0.59 
BASFI-score (0-10)* 2.49 (1.77) 2.41 (1.70) 0.73 2.53 (0.21) 2.40 (0.20) 0.63 
BASMI score (0-10)* 2.64 (0.25) 3.02 (0.24) 0.27 2.40 (0.28) 2.66 (0.28) 0.46 
OIMQ (MET per week) 51.37 (6.27) 55.40 (6.39) 0.65 52.94 (7.24) 58.03 (7.51)  0.61 
Accelerometer, counts/min), mean (SD) 333.35 (22.16) 335.34 0.95 373.98 (30.00) 349.87 0.45 
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per day (20.44) (24.95) 
Accelerometer, moderate activity 141.17 (8.55) 147.81 (7.94) 0.57 149.14 (11.58) 146.58 (9.53) 0.83 
PA (Accelerometer, units of vigorous 
activity) 
7.45 (1.25) 9.50 (1.32) 0.26 8.74 (1.77) 9.36 (1.52) 0.74 
Resting heart rate 81.10 (1.95) 81.57 (1.86) 0.86 77.89 (1.93) 80.27 (1.91) 0.33 
Heart rate at end of test 128.30 (0.59) 128.37 (0.59) 0.93 128 92 (0.69) 128.70 (0.68) 0.80 
HADS Anxiety (0-21) 6.27 (0.35) 6.58 (0.34) 0.52 6.58 (0.40) 6.63 (0.39) 0.93 
HADS Depression (0-21) 5.10 (0.31) 4.48 (0.30) 0.16 5.18 (0.37) 4.33 (0.35) 0.07 
EURO-Quol Health score (0-100) 64.24 (3.05) 63.01 (2.93) 0.77 61.97 (3.31) 65.19 (3.13) 0.44 
ASDAS(CRP)* 2.26 (0.15) 2.16 (0.15) 0.62 2.43 (0.17) 2.23 (0.18) 0.38 
CRP (mg/l)* 6.27 (1.08) 4.95 (1.07) 0.39 7.49 (1.22) 4.93 (1.30) 0.12 
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Cholesterol (mmol/l)* 5.66 (0.15) 5.90 (0.16) 0.28 5.66 (0.18) 5.93 (0.19) 0.24 
Triglycerides (mmol/l)* 1.30 (0.12) 1.42 (0.13) 0.48 1.23 (0.14) 1.35 (0.16) 0.52 
All values are means and standard deviation (SD), unless stated otherwise. 
*Adjusted for TNF alpha and baseline level of the characteristic 
** adjusted for age, sex, BMI, smoking status, baseline physical activity, baseline fitness level, BASDAI, TNF alpha treatment and 
baseline level of the characteristic 
BAS-G = Bath AS Patient Global Score; BASFI = the Bath AS Functional Index; BASMI = Bath AS Metrology Index; PA = Physical 
Activity; OIMQ = Office in Motion Questionnaire; MET, metabolic equivalents; HADS = Hospital Anxiety and Depression Scale; EURO-
Quol = quality of life questionnaire; AS DASCRP, ankylosing spondylitis disease activity score (calculated with CRP values); CRP, C-
reactive protein; 
Patients randomly 
assigned (n=106)
To cardiovascular training CVT (n=53) 
Performed at least 3 CVT/week (n=40)
Not performed at least 1 CVT/week (n=8)
To attention control (AC) sessions (n=53) 
Attended at least 2 AC sessions (n=32)
Not attended at least 1 AC session (n=10)
Performed CVT, mean 1 unit/week (n=20)
Loss to follow-up (n=4) 
Exacerbation of disease/co-morbidities (n=3)
Not reachable (n=1)
Loss to-follow-up (n=3)
Exacerbation of disease/co-morbidities (n=2)
Not reachable (n=1)
Assessed for eligibility
(n=185) No participation (n=79)
Refused to participate (n=77)
Not meeting inclusion criteria (n=2)
Figure 1: Trial flow chart
Eligibility (n not noted)
